Hipoglikemia

01Pathophysiology

Glucose is the primary fuel for the central nervous system, and the brain cannot synthesize or store meaningful amounts of it. Under normal conditions, falling blood glucose triggers a coordinated counter-regulatory response. Glucagon is the first-line defense, stimulating hepatic glycogenolysis and gluconeogenesis. If glucose continues to fall, epinephrine is released, producing the classic adrenergic symptoms: tremor, diaphoresis, palpitations, and anxiety. These autonomic warning signs typically appear at a glucose level around 55 to 65 mg/dL and serve as an early alarm before the brain is compromised.

When glucose drops further (generally below 50 mg/dL), the brain begins to malfunction due to neuroglycopenia. This manifests as confusion, difficulty concentrating, slurred speech, behavioral changes, seizures, and eventually coma. The distinction between adrenergic and neuroglycopenic symptoms is critical for exam purposes because some patients, particularly those with longstanding diabetes or recurrent hypoglycemia, develop hypoglycemia unawareness. In this condition, repeated episodes blunt the autonomic response, meaning the patient loses the early warning signs and presents directly with neuroglycopenic features such as confusion or seizure without any preceding tremor or diaphoresis.

The concept of Whipple triad anchors the clinical definition of hypoglycemia: (1) symptoms consistent with hypoglycemia, (2) a documented low plasma glucose at the time of symptoms, and (3) resolution of symptoms after glucose correction. This triad is especially important when evaluating non-diabetic patients, where the finding of hypoglycemia demands further investigation into the underlying cause.

In the fasting state, the body relies on hepatic gluconeogenesis (from amino acids, lactate, and glycerol) and glycogenolysis to maintain blood glucose. Any process that impairs these pathways (liver disease, alcohol ingestion, cortisol deficiency) or overwhelms them with excess insulin (insulinoma, exogenous insulin, sulfonylureas) will produce hypoglycemia. Alcohol deserves special mention: ethanol metabolism consumes NAD+, which is required for gluconeogenesis. This is why alcohol-induced hypoglycemia classically occurs after a period of fasting combined with heavy drinking, when glycogen stores are already depleted.

02Classification and Clinical Manifestation

By Clinical Context

Symptom Classification

Hypoglycemia Severity (International Hypoglycemia Study Group)

03Diagnostic Workup

The workup begins with confirming the Whipple triad. A point-of-care fingerstick glucose is the best initial test in any patient presenting with symptoms suggestive of hypoglycemia. Once a low glucose is documented and symptoms resolve with correction, the next question is whether the patient is diabetic or non-diabetic, because this determines the direction of the evaluation.

In diabetic patients, the cause is almost always drug-related. The workup focuses on reviewing the medication list (insulin, sulfonylureas, meglitinides), assessing for dose errors, missed meals, increased physical activity, renal impairment (which prolongs insulin and sulfonylurea half-life), or new drug interactions. Extensive biochemical testing is usually unnecessary.

In non-diabetic patients with confirmed hypoglycemia, the critical question is whether the hypoglycemia is insulin-mediated. This requires a simultaneous panel drawn during a hypoglycemic episode: plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and a sulfonylurea/meglitinide screen. The interpretation of this panel is one of the highest-yield concepts on the exam:

If spontaneous hypoglycemia cannot be captured, the 72-hour supervised fast is the gold standard provocative test for insulinoma. The patient fasts under observation, with glucose, insulin, C-peptide, and proinsulin measured every 6 hours (and every 1 to 2 hours once glucose drops below 60 mg/dL). The fast is terminated when glucose falls below 45 mg/dL with symptoms or below 55 mg/dL with documented Whipple triad. An inappropriately elevated insulin (>= 3 microU/mL), elevated C-peptide (>= 0.6 ng/mL), and elevated proinsulin (>= 5.0 pmol/L) during hypoglycemia confirm endogenous hyperinsulinism. Over 95% of insulinomas will manifest within 48 hours, and nearly all within 72 hours.

Imaging with CT or MRI of the abdomen (using thin-cut pancreatic protocol) is only performed after biochemical confirmation, not as a screening test. Endoscopic ultrasound has the highest sensitivity for localizing small pancreatic insulinomas.

04Management and Treatment

Acute stabilization follows a simple algorithm. For a conscious patient who can protect their airway, the Rule of 15 applies: administer 15 to 20 grams of fast-acting carbohydrate (4 glucose tablets, 4 oz of juice, or 8 oz of skim milk), wait 15 minutes, recheck glucose, and repeat if still below 70 mg/dL. Once glucose normalizes, the patient should eat a mixed meal or snack containing protein and complex carbohydrates to prevent recurrence.

For an unconscious patient or one who cannot safely swallow, IV dextrose is the treatment of choice. The standard dose is 25 grams, given as 50 mL of D50W by IV push. In neonates and children, lower concentrations are used: D10W at 2 to 4 mL/kg for neonates and D25W for children, because D50W is hyperosmolar and can cause phlebitis or tissue injury. If IV access is unavailable, glucagon 1 mg IM is the alternative. Glucagon works by stimulating hepatic glycogenolysis, so it will be ineffective in patients with depleted glycogen stores (prolonged fasting, alcohol use, liver failure).

Sulfonylurea-induced hypoglycemia is a high-yield management trap. These drugs have long half-lives (glipizide: 12 to 24 hours; glyburide: up to 24 hours), and the hypoglycemia tends to recur after initial correction. Dextrose infusion alone can paradoxically worsen the problem by stimulating further insulin release. The key intervention is octreotide, a somatostatin analog that inhibits insulin secretion from beta cells. Octreotide is given at 50 to 100 mcg SC every 6 to 8 hours. All patients with sulfonylurea-induced hypoglycemia require admission and observation for at least 24 hours due to the risk of recurrence.

For insulinoma, surgical resection (enucleation or distal pancreatectomy) is the definitive treatment and is curative in over 90% of cases. In patients who are not surgical candidates, diazoxide (which opens potassium channels on beta cells to suppress insulin secretion) or everolimus can be used for medical management.

When treating alcohol-related hypoglycemia, always administer thiamine (100 mg IV) before or simultaneously with dextrose to prevent precipitating Wernicke encephalopathy. This is a classic "never miss" principle on the exam.

Long-term management in diabetic patients involves adjusting the medication regimen: reducing insulin dose, switching from sulfonylureas to agents with lower hypoglycemia risk (metformin, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors), and educating patients on self-monitoring, carbohydrate intake, and recognition of warning symptoms.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on hypoglycemia questions involves failing to distinguish the cause in a non-diabetic patient. The exam frequently presents a "seemingly healthy" patient with recurrent fasting hypoglycemia and asks for the next step. The trap is to jump straight to imaging. The correct answer is always to obtain the critical biochemical panel first (insulin, C-peptide, proinsulin, beta-hydroxybutyrate, sulfonylurea screen) during a documented hypoglycemic episode. Imaging is never the first step.

A second classic trap is the sulfonylurea management question. Students recognize that the patient needs dextrose, but they forget that dextrose alone can worsen hypoglycemia in the setting of sulfonylurea use by stimulating further insulin release. The tested answer is octreotide as adjunctive therapy, plus prolonged observation. Never discharge a sulfonylurea-overdose patient after a single glucose correction.

Another tested concept is hypoglycemia unawareness. The vignette will describe a type 1 diabetic with recurrent episodes who no longer experiences warning symptoms and presents with seizure or confusion. The management involves raising glycemic targets temporarily and avoiding hypoglycemia for 2 to 3 weeks to restore the autonomic response threshold.

Always check glucose before diagnosing stroke. This is a patient safety pearl that appears repeatedly: a patient presenting with focal neurologic deficits and altered mental status should have a point-of-care glucose checked immediately. Severe hypoglycemia can perfectly mimic stroke, and the treatment is glucose, not thrombolytics.

Finally, remember the C-peptide pattern. Exogenous insulin administration suppresses endogenous insulin production, so C-peptide will be low. In insulinoma, the beta cells are autonomously producing insulin along with C-peptide, so both will be elevated. In sulfonylurea ingestion, both insulin and C-peptide are elevated (because the drug stimulates endogenous secretion), but the sulfonylurea screen will be positive. This three-way distinction is among the most frequently tested concepts in endocrinology.